Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00556764 | Development of Cognitive Assessment Tools in Parkinson Disease | EARLY_PHASE1 | COMPLETED | 75 | — | — | Jul 1, 2007 | Mar 1, 2011 | Feb 9, 2012 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 2 cohorts | EXPERIMENTAL | In this observational study 2 cohorts will participate. Cohort 1 will include people with Parkinson disease and Cohort 2 will include healthy volunteers. A subset of twelve subjects (8 PD and 4 HC) will be enrolled in the \[123I\] IBVM and SPECT imaging portion of this study |
| Name | Type | Description |
|---|---|---|
| [123I] IBVM and SPECT imaging | DRUG | Subjects will be injected with up to 4 mCi of 123-I IBVM followed by SPECT imaging. |
| Subjects will undergo the 123-I IBVM imaging visit | DRUG | Subjects will be injected with a bolus of up to 4 mCi of 123-I IBVM followed by serial SPECT imaging. |
Inclusion and Exclusion Criteria PD subjects Inclusion criteria: * The participant is 30 years or older. * Written informed consent is obtained. * Participants have a clinical diagnosis of Parkinson's disease based on Brain Bank Criteria. * Mini-mental status examination (MMSE) score ≥24 or signi...